ALK Positive, Inc is a resource and community for patients, care-partners and supporters helping to improve the life expectancy and quality of life for ALK-positive cancer patients worldwide.
The biomarker collaborative groups work together and with others on issues that impact all cancer patients. These initiatives include patient engagement, improved screening, comprehensive biomarker testing, and modernization of clinical trials.
BRAF Bombers is a biomarker group for patients with lung cancer to share information and to help and support one another.
EGFR Resisters is a grassroots patient-driven community, dedicated exclusively to changing EGFR-positive lung cancer into a manageable, chronic disease.
The Exon 20 Group, founded in 2017, provides more than 20 services to EGFR exon 20 insertion patients and HER2 exon 20 insertion patients diagnosed with lung cancer or 24 other cancer types.
KRAS Kickers connects people to current research, resources, and community to Kick Cancer's KRAS! Empowering the KRAS community with: K–KRAS knowldege; R–Research, resources; A–Advocacy, alliances; S–Survivorship, science.
This is a community of patients with lung cancer, caregivers, advocates, researchers, and physicians dedicated to helping patients with the MET alteration live normal lives.
This is a growing community of patients and loved ones who aren’t afraid to ask questions. They work closely with medical experts and patient advocacy leaders to improve knowledge, testing, and research for NTRK fusion–positive cancer.
A patient-driven group and nonprofit organization that aims to improve the quality of life and life expectancy of patients with RET-positive cancer through increased awareness, emotional support, advocacy, and medical research funding for RET-driven cancer.
The ROS1ders is a global group of patients and caregivers living with ROS1-positive cancer. They seek to help improve outcomes for all ROS1-positive cancers through community, education, and research.
Genentech does not control or endorse the content of the third-party websites listed here, and Genentech makes no representation as to the accuracy of the information contained on these websites. The information provided by these organizations is meant for informational purposes only and is not meant to replace a doctor’s medical advice. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.
Non–small cell lung cancer (NSCLC)
The most common form of lung cancer, which is described by the way the cancer cells look under a microscope (not small).
A treatment that targets the driver mutations that cause cancer growth.
The information contained in this section of the site is intended for U.S. healthcare professionals only. Click "OK" if you are a healthcare professional.
The link you have selected will take you away from this site to one that is not owned or controlled by Genentech, Inc. Genentech, Inc. makes no representation as to the accuracy of the information contained on sites we do not own or control. Genentech does not recommend and does not endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.